SPY302.97-0.56 -0.18%
DIA254.35-1.42 -0.56%
IXIC9,368.99-43.37 -0.46%

UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $15

UBS maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $12 to $15.

Benzinga · 05/11/2020 14:08

UBS maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $12 to $15.